An expert panel of India s central drug authority on Saturday recommended granting permission for restricted emergency use of the indigenously developed COVID-19 vaccine Covaxin with certain conditions, a day after giving similar direction for the Oxford COVID-19 vaccine, sources said.
Updated Jan 03, 2021 | 13:41 IST
Covaxin is a highly purified and inactivated 2 dose SARS-CoV2 vaccine, manufactured in a Vero cell manufacturing platform with an excellent safety track record of more than 300 million doses. Representational Image
Hyderabad: Expressing delight on the Ministry of Health & Family Welfare announcement and the statement from DCGI - Central Standards Control Organization (CDSCO) Grant of permission for emergency use of its Covid-19 Vaccine today, the Chairman and Managing Director of Bharat Biotech Dr Krishna Ella said “The approval of COVAXIN™ for emergency use is a giant leap for Innovation and novel product development in India. It is a proud moment for the nation and a great milestone in India’s scientific capability, a kickstart to the innovation ecosystem in India. While this vaccine addresses an unmet medical need during this pandemic, our goal is to provide global access to populations that need it the mo
The Straits Times
India okays 2 vaccines, paving way for massive inoculation drive
Mock candidates in the waiting area during a dry run for vaccinations at a model Covid-19 vaccination centre in New Delhi on Saturday. India is now expected to start a massive immunisation programme within about a week, a government official said, and hopes to inoculate 300 million of its 1.35 billion people free of charge in the first six to eight months of this year.PHOTO: EPA-EFE
A health official preparing a vaccine kit as she took part in a dry run for Covid-19 vaccine delivery at a primary health centre in Chennai on Saturday. PHOTO: AGENCE FRANCE-PRESSE
COVID-19: Expert committee recommends restricted emergency use of SII, Bharat Biotech s vaccines ANI | Updated: Jan 02, 2021 21:51 IST
New Delhi [India], January 2 (ANI): The Subject Expert Committee (SEC) of Central Drugs Standards Control Organisation on Saturday made recommendations to the Drugs Controller General of India to grant permission for restricted emergency use of SII, Bharat Biotech s vaccines.
As per an official release, the SEC met on Friday and Saturday and made its recommendations in respect of accelerated approval process request of Serum Institute of India (SII), Bharat Biotech International Ltd as well as about phase-III trials of Cadila Healthcare Ltd. Grant of permission for restricted emergency use of the vaccine, subject to multiple regulatory conditionalities, to Serum Institute of India, Pune, it said.
SEC makes recommendations to speed up process to consider Indian COVID-19 candidates
The Subject Expert Committee has made recommendations to speed up the process of COVID-19 vaccine candidates being developed by Serum Institute of India, Bharat Biotech and Zydus Cadilla on January 2.
Source: Reuters
The Subject Expert Committee (SEC) has made recommendations to speed up the process to consider COVID-19 vaccine candidates being developed by Serum Institute of India, Bharat Biotech and Cadilla Healthcare on January 2. The Subject Expert Committee (SEC) of Central Drugs Standards Control Organisation (CDSCO) makes recommendations in respect of Accelerated Approval Process request of M/s Serum Institute of India and M/s Bharat Biotech International Ltd as well as about Phase-III Trials of M/s Cadila Healthcare Ltd, the statement issued by the central government said.